Bli medlem
Bli medlem

Du är här

2021-02-25

Coegin Pharma AB: BioStock: Coegin Pharma's clinical development in actinic keratosis

Actinic keratosis (AK) is one of the most common skin disorders and can be a first step in the development of skin cancer. Patients undergoing conventional AK treatments frequently experience pain, bleeding, inflammation, and scarring. Consequently, new and better treatment options to reduce patient side effects such as skin damage are high demand. The Nordic biotech Coegin Pharma will soon start clinical evaluation of its candidate AVX001 as a potential new and better treatment of AK. BioStock was able to speak with the lead clinician in the clinical program, Professor Merete Hædersdal, to learn more about AK and Coegin Pharma's clinical development program.

Read the full interview with Merete Hædersdal at biostock.se:

https://www.biostock.se/en/coegin-pharmas-clinical-development-in-actinic-keratosis/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.